People living with borderline personality disorder often face unstable emotions, strained relationships and a high risk of self harm, yet many struggle to access effective treatment. New research suggests that psychedelic drugs, including ketamine and psilocybin, could offer a different path by targeting the underlying symptoms that make the condition so difficult to manage. The findings add to growing interest in alternative mental health treatments, particularly for patients who do not respond to standard care. The findings were published in Psychiatry Research.
Borderline personality disorder affects emotional regulation, behaviour and sense of identity, and is linked to higher rates of suicide than many other psychiatric conditions. Current treatment relies heavily on specialist psychotherapy such as dialectical behaviour therapy, which can take months or years and is often difficult to access. There are no medications specifically approved for the condition, leaving a clear gap in care.
The new review analysed 22 studies involving psychedelic substances, including ketamine, esketamine and psilocybin. These studies covered a range of designs, from clinical trials to case reports, reflecting how early the research still is. Most of the evidence focused on ketamine, which has already been explored for depression and anxiety.
Across several studies, patients showed improvements in key symptoms such as emotional instability, impulsivity and suicidal thoughts. In one analysis of patients with treatment resistant depression, those with borderline personality disorder experienced meaningful reductions in symptom severity after repeated ketamine infusions. Some individuals also reported better social functioning and improved ability to manage stress.
Case studies offer further insight into how these treatments might work in practice. Patients receiving ketamine or esketamine over weeks or months showed reduced self harm behaviours, improved relationships and, in some cases, no longer met diagnostic criteria for the disorder. These changes were often accompanied by improvements in mood, anxiety and daily functioning, suggesting a broader impact on mental health.
Researchers believe these effects may be linked to how psychedelics act on the brain. Ketamine, for example, influences glutamate signalling and may promote neuroplasticity, allowing the brain to form new connections and patterns of thinking. Psilocybin has been linked to changes in self perception and increased emotional openness, which could be relevant for people who struggle with identity and interpersonal relationships.
But the evidence is far from definitive. Many of the studies involved small samples, lacked control groups or combined psychedelic treatment with other therapies, making it difficult to isolate the effects. People with borderline personality disorder have also historically been excluded from clinical trials due to concerns about safety, particularly around suicidality and substance misuse.
Safety remains a key concern. While most studies reported that side effects were mild and short lived, including dizziness, nausea and temporary dissociation, there were cases where symptoms worsened. Some patients experienced increased impulsivity or suicidal thoughts during treatment, highlighting the need for careful monitoring and structured clinical settings.
Experts caution that these treatments are not ready for widespread use. Larger, well designed trials are needed to determine who might benefit, what doses are safe and how these therapies should be delivered alongside existing treatments. Ongoing clinical trials are beginning to address these questions, including studies of ketamine, psilocybin and MDMA in patients with borderline personality disorder.
The growing body of research suggests that psychedelics may eventually become part of a broader toolkit for treating complex mental health conditions. For now, they remain an experimental option, but one that could reshape how borderline personality disorder is managed in the future.